Cell Therapy News/Articles, page-3749

I compare the mortality of the n=12 Remestemcel-L treatment of ventilator patients to other hospital mortality experience at the time which was 17% to 78%, to the latest study recently quoted by RECOVERY Collaborative Group, of dexamethasone (ventilator at time of randomisation) with mortality after 28 days of 29.0% dexamthasone versus 40.7% best care.

Firstly notice that best care mortality has decreased from 78% to around 41% as treatment regimes have improved for ventilator patients. Being on a ventilator is not the death sentence it was 3 months ago when less was known about how to treat moderate to severe cases.

Secondly, be aware that due to the small sample size of 12 of the initial Remestemcel-L trial, the outcome if there had been 3 deaths and not 2 (out of 12), then the mortality would have been 25%. Compared to current treatment regime mortality of 41% this is still pretty good, but not much better than dexamethasone with 29%, which is cheaper than Remestemcel-L.

I hope this helps some of the more statistically minded investors out there. FWIW I studied actuarial science back in the day. I conclude there is a pretty good chance that Remestemcel-L beats Dexamethasone for 30 day mortality when the comparable standard clinical trial results are in (ie. double blinded randomised large n value) but it is not certain due to the inherent small sample size variability. n=30 initial read-out could be available mid-July IMO and will give a much idea of how effective Remestemcel-L is in reducing 30 day mortality.